Early preclinical studies have demonstrated that KRAS-targeting PROTACs, including degraders specific for KRAS G12D and KRAS G12V mutants, effectively reduce KRAS protein levels and suppress downstream MAPK signaling in various cancer cell lines and xenograft models [88,89]. Here, KRAS is linked to cancer.